William Taylor
Hematology & Oncology · Mobile, ALNPI 1114166139
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 13 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 9 manufacturers, the largest accounting for just 17.8% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for hematology & oncology clinicians in AL, where the typical reported total is $7,159.
Across 13 payments — averaging $16.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$38
- Johnson & Johnson$36
- Bristol Myers Squibb$33
- Eisai Inc.$22
- Genentech USA, Inc.$19
- Novartis$19
- plus $46 from 3 others
What the payments were for
- Food & beverage$213100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 3 | $38 |
| Johnson & Johnson | 2 | $36 |
| Bristol Myers Squibb | 2 | $33 |
| Eisai Inc. | 1 | $22 |
| Genentech USA, Inc. | 1 | $19 |
| Novartis | 1 | $19 |
| AstraZeneca | 1 | $16 |
| Incyte Corporation | 1 | $15 |
| Blueprint Medicines Corporation | 1 | $15 |
How this compares
$213 in reported general payments places this provider in the 5th percentile of 177 hematology & oncology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Letrozole | 12 | $195 |
| Prednisone | 11 | $139 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Mobile
- Anita MazloomMobile$20K
- Sherri ArledgeMobile$19K
- Daniel CameronMobile$17K
- Jose Galeas SorianoMobile$17K
- Michael MeshadMobile$14K
- Amitkumar MehtaBirmingham$683K
- Pankit VachhaniBirmingham$545K
- Luciano CostaBirmingham$409K
- Khaleel AshrafBirmingham$379K
- Michael BirrerBirmingham$302K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.